Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

This study has been completed.
Astellas Pharma Inc
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd Identifier:
First received: September 13, 2005
Last updated: October 10, 2012
Last verified: October 2012

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Condition Intervention Phase
Involutional Osteoporosis
Drug: ONO-5920
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Resource links provided by NLM:

Further study details as provided by Ono Pharmaceutical Co. Ltd:

Primary Outcome Measures:
  • New fragility vertebral fracture

Secondary Outcome Measures:
  • New clinical fracture, biochemical markers of bone turnover, height, mean bone mineral density of the lumbar spoine (L2-4 BMD), lower back pain

Estimated Enrollment: 650
Study Start Date: August 2002
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   55 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with fragility fracture according to the diagnostic criterial for the diagnosis of Primary Osteoporosis
  2. Patients having radiographically confirmed vertebral (T4-L4) fractures
  3. Other inclusion criteria as specified in the study protocol

Exclusion Criteria:

  1. Patients having secondary osteoporosis or another condition that presents low bone mass
  2. Patients having findings on X-ray that affect evaluation of vertebral fracture
  3. Patients that have been administered bisphosphonate derivatives
  4. Other exclusion criteria as specified in the study protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00212667

Sponsors and Collaborators
Ono Pharmaceutical Co. Ltd
Astellas Pharma Inc
Study Director: Project Leader, Development Planning Ono Pharmaceutical Co. LtTd.
  More Information

No publications provided by Ono Pharmaceutical Co. Ltd

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ono Pharmaceutical Co. Ltd Identifier: NCT00212667     History of Changes
Obsolete Identifiers: NCT00189891
Other Study ID Numbers: ONO-5920-02
Study First Received: September 13, 2005
Last Updated: October 10, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Ono Pharmaceutical Co. Ltd:
ONO-5920, osteoporosis, bisphosphonate

Additional relevant MeSH terms:
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases processed this record on November 20, 2014